Home » MORPHOSYS TO DEVELOP ANTIBODIES FOR CENTOCOR
MORPHOSYS TO DEVELOP ANTIBODIES FOR CENTOCOR
German biotech firm MorphoSys (MORG.DE: Quote, Profile, Research) said on Tuesday it will develop antibodies for a new target molecule for Centocor Inc., a Johnson & Johnson (JNJ.N: Quote, Profile, Research) company. MorphoSys, which entered into a collaboration with Centocor in 2000 to develop antibodies for a wide range of indications, said Centocor will carry out pre-clinical and clinical development and the subsequent marketing of resulting products.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May